WO2023198640 - MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
National phase entry:
Publication Number
WO/2023/198640
Publication Date
19.10.2023
International Application No.
PCT/EP2023/059303
International Filing Date
07.04.2023
Title **
[English]
MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
[French]
FORMULATIONS PHARMACEUTIQUES À LIBÉRATION MODIFIÉE COMPRENANT DE LA DÉFÉRIPRONE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
PERTILE, Marisa
c/o Chiei Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
GAZZANIGA, Andrea
c/o Università degli studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
CEREA, Matteo
c/o Università degli studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
CIRILLI, Micol
c/o Università degli studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
Priority Data
22167555.6
11.04.2022
EP
17/717,922
11.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1299 | |
| EPO | Filing, Examination | 6183 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 2710 |
Total: 11386 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit delayed release properties when administered as either whole or half tablets. In particular, the invention is directed to delayed release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The invention is also directed to methods of making and using the same.[French]
L'invention concerne des compositions pharmaceutiques destinées à être administrées par voie orale sous la forme de comprimés enrobés qui présentent des propriétés de libération retardée lorsqu'ils sont administrés sous forme de comprimés entiers ou de demi-comprimés. En particulier, l'invention concerne des comprimés à libération retardée comprenant de la défériprone, lesdits comprimés étant appropriés pour une administration orale deux fois par jour. L'invention concerne également leurs procédés de production et d'utilisation.